Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Finding Novel targets for combination therapies with Kirsten rat sarcoma viral oncogene homolog-G12C inhibitors in drug-resistant lung cancer

EF 2024-25

Résumé
Lung cancer related mortality remains the highest globally, with non-small cell lung cancer (NSCLC) as the most common type of lung cancer. Among NSCLC cases, 13% involve KRAS-G12C mutation, a historically challenging target for drug development. While recent KRAS-G12C inhibitor drugs, such as Sotorasib, have demonstrated some efficacy, their response rates remain suboptimal, with most patients displaying innate resistance. Addressing this resistance is critical to improving outcomes.This study explores the concept of synthetic lethality as an avenue to overcome innate resistance in KRAS-G12C mutant lung cancer. Synthetic lethality occurs when disruption of two genes leads to cell death, but the disruption of either one of the genes leads to cell survival. Through the utilization of high-throughput screening (HTS) of drug libraries on patient-derived lung organoid models that display innate resistance to KRAS-G12C inhibitors, we aim to identify novel genes that are synthetically lethal with KRAS in these drug-resistant cancer cells.The HTS process involves testing large library of compounds, including Kinase inhibitors and FDA-approved drugs, on the resistant organoids treated with Sotorasib, a KRAS-G12C inhibitor. Candidate genes identified as synthetic lethal targets will undergo validation using CRISPR/Cas9.This research seeks to identify novel therapeutic targets to be used in combination with KRAS-G12C inhibitors, paving the way for more effective treatments. By addressing innate resistance, this work has the potential to significantly improve survival rates and quality of life for lung cancer patients with KRAS-G12C mutations.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530153
Name
Wang Mutian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Finding Novel targets for combination therapies with Kirsten rat sarcoma viral oncogene homolog-G12C inhibitors in drug-resistant lung cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr/Cas 9; High Throughput Drug Screen; Kras G12c; Non Small Lung Cancer; Primary Resistance; Synthetic Lethality; Tumour Organoids
Abstract
Lung cancer related mortality remains the highest globally, with non-small cell lung cancer (NSCLC) as the most common type of lung cancer. Among NSCLC cases, 13% involve KRAS-G12C mutation, a historically challenging target for drug development. While recent KRAS-G12C inhibitor drugs, such as Sotorasib, have demonstrated some efficacy, their response rates remain suboptimal, with most patients displaying innate resistance. Addressing this resistance is critical to improving outcomes.This study explores the concept of synthetic lethality as an avenue to overcome innate resistance in KRAS-G12C mutant lung cancer. Synthetic lethality occurs when disruption of two genes leads to cell death, but the disruption of either one of the genes leads to cell survival. Through the utilization of high-throughput screening (HTS) of drug libraries on patient-derived lung organoid models that display innate resistance to KRAS-G12C inhibitors, we aim to identify novel genes that are synthetically lethal with KRAS in these drug-resistant cancer cells.The HTS process involves testing large library of compounds, including Kinase inhibitors and FDA-approved drugs, on the resistant organoids treated with Sotorasib, a KRAS-G12C inhibitor. Candidate genes identified as synthetic lethal targets will undergo validation using CRISPR/Cas9.This research seeks to identify novel therapeutic targets to be used in combination with KRAS-G12C inhibitors, paving the way for more effective treatments. By addressing innate resistance, this work has the potential to significantly improve survival rates and quality of life for lung cancer patients with KRAS-G12C mutations.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Mutian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~